Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ionomycin vs A23187 for Artificial Oocyte Activation
NCT06106412Recruiting
- Sponsor
- IVI
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ionomycin and calcium ionophore A23187 in infertility, sponsored by IVI. Primary endpoint: Usable blastocyst per injected oocyte at 1 year. Started Jan 2024; status: recruiting.
02
Drugs
ionomycincalcium ionophore A23187
03
Conditions
infertility
Beyond the preview
Go deeper on NCT06106412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106412.